

---

# Guidance for Industry

## Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations

### *DRAFT GUIDANCE*

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact the CDER Office of Clinical Pharmacology at 301-796-5008 or [OCP@fda.hhs.gov](mailto:OCP@fda.hhs.gov).

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**March 2014  
Biopharmaceutics**

---

# Guidance for Industry

## Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs— General Considerations

*Additional copies are available from:*

*Office of Communications  
Division of Drug Information, WO51, Room 2201  
Center for Drug Evaluation and Research  
Food and Drug Administration  
10903 New Hampshire Avenue, Silver Spring, MD 20993  
<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>  
Phone: 301-796-3400; Fax: 301-847-8714  
[druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov)*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**March 2014  
Biopharmaceutics**

# TABLE OF CONTENTS

<b>I. INTRODUCTION.....</b>	<b>1</b>
<b>II. BACKGROUND .....</b>	<b>2</b>
A. GENERAL .....	3
B. BIOAVAILABILITY .....	3
C. BIOEQUIVALENCE .....	4
<b>III. METHODS TO DOCUMENT BA AND BE .....</b>	<b>6</b>
A. PHARMACOKINETIC STUDIES .....	6
B. OTHER APPROACHES TO SUPPORT BA/BE.....	10
<b>IV. DOCUMENTING BA AND BE FOR VARIOUS DOSAGE FORMS .....</b>	<b>12</b>
A. SOLUTIONS AND OTHER SOLUBILIZED DOSAGE FORMS.....	12
B. IMMEDIATE-RELEASE PRODUCTS.....	12
C. MODIFIED-RELEASE PRODUCTS.....	13
D. BATCH SIZE .....	16
<b>V. ADDITIONAL INFORMATION ON IN VITRO APPROACHES.....</b>	<b>16</b>
A. IN VITRO STUDIES CONDUCTED IN SUPPORT OF A WAIVER OF AN IN VIVO BA OR BE DATA REQUIREMENT .....	16
B. IN VITRO STUDIES CONDUCTED IN SUPPORT OF DEMONSTRATING BA OR BE .....	17
<b>VI. SPECIAL TOPICS .....</b>	<b>20</b>
A. ALCOHOLIC BEVERAGE EFFECTS ON MR DRUG PRODUCTS .....	20
B. ENANTIOMERS VERSUS RACEMATES.....	20
C. DRUG PRODUCTS WITH COMPLEX MIXTURES AS THE ACTIVE INGREDIENTS .....	20
D. LONG-HALF-LIFE DRUGS .....	21
E. ORALLY ADMINISTERED DRUGS INTENDED FOR LOCAL ACTION.....	21
F. COMBINATION/COADMINISTERED DRUG PRODUCTS .....	21
G. ENDOGENOUS SUBSTANCES.....	22
H. DRUG PRODUCTS WITH HIGH INTRASUBJECT VARIABILITY .....	23
<b>APPENDIX A: GENERAL STUDY DESIGN AND DATA HANDLING.....</b>	<b>24</b>

## **Guidance for Industry<sup>1</sup>**

### **Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations**

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

#### **I. INTRODUCTION**

This guidance provides recommendations to sponsors and/or applicants planning to include bioavailability (BA) and bioequivalence (BE) information for drug products in investigational new drug applications (INDs), new drug applications (NDAs), and NDA supplements (referred to as the NDA BA and BE Draft Guidance).<sup>2</sup> This guidance contains advice on how to meet the BA and BE requirements set forth in 21 CFR part 320 as they apply to dosage forms intended for oral administration.<sup>3</sup> The guidance may also be applicable to non-orally administered drug products when reliance on systemic exposure measures is suitable to document BA and BE (e.g., transdermal delivery systems and certain rectal and nasal drug products). The guidance should be helpful for applicants conducting BA and BE studies during the IND period for an NDA and also for applicants conducting BE studies during the postapproval period for certain changes to

---

<sup>1</sup> This guidance was developed by the Office of Clinical Pharmacology, Office of Translational Sciences, and the Office of New Drugs Quality Assessment, Office of Pharmaceutical Science, in the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA).

<sup>2</sup> BA and BE information for drug products in abbreviated new drug applications (ANDAs) and ANDA supplements are not the subject of this guidance. FDA has issued a separate draft guidance on this topic entitled *Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA* (December 2013) (ANDA BE Draft Guidance). The ANDA BE Draft Guidance, when finalized, will represent FDA's current thinking on this topic. Many guidances are referenced throughout this document. The guidance referred to in this footnote, as well as others referenced throughout the remainder of the document, can be found on the FDA Drugs guidance Web page at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>. We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs guidance Web page.

<sup>3</sup> These dosage forms include tablets, capsules, solutions, suspensions, conventional/immediate-release drug products, and modified (extended, delayed)-release drug products.

*Draft — Not for Implementation*

*Contains Nonbinding Recommendations*

28 drug products that are the subject of an NDA.<sup>4</sup> This guidance document is not intended to  
29 provide recommendations on studies conducted in support of demonstrating comparability or  
30 biosimilarity for biological products licensed under section 351 of the Public Health Service  
31 Act.<sup>5</sup>

32  
33 When finalized, this guidance will revise and replace the parts of FDA’s March 2003 guidance  
34 for industry on *Bioavailability and Bioequivalence Studies for Orally Administered Drug*  
35 *Products – General Considerations* (the March 2003 BA and BE Guidance) relating to BA and  
36 BE studies for INDs, NDAs, and NDA supplements.<sup>6</sup> Since the March 2003 BA and BE  
37 Guidance was issued, FDA has determined that providing information on BA and BE studies in  
38 separate guidances according to application type will be beneficial to sponsors and applicants.  
39 Thus, FDA is issuing this NDA BA and BE Draft Guidance and, as previously noted, has issued  
40 the ANDA BE Draft Guidance for ANDA and ANDA supplements.<sup>7</sup>

41  
42 We recognize that this guidance cannot address every issue pertaining to the assessment of BA  
43 or BE studies for INDs and NDAs, so we suggest sponsors and applicants contact the appropriate  
44 review division for guidance on specific questions not addressed by this guidance.

45  
46 FDA's guidance documents, including this guidance, do not establish legally enforceable  
47 responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should  
48 be viewed only as recommendations, unless specific regulatory or statutory requirements are  
49 cited. The use of the word *should* in Agency guidance documents means that something is  
50 suggested or recommended, but not required.

51  
52 **II. BACKGROUND**

53  

---

<sup>4</sup> *Bioequivalence* is a statutory term reflected in the Federal Food, Drug, and Cosmetic Act (FD&C Act) in section 505(j) (21 U.S.C. 355(j)), which requires ANDA applicants to demonstrate, among other things, that the proposed generic product is bioequivalent to its reference listed drug. Section 505(j)(2)(A)(iv) of the FD&C Act; see also section 505(j)(8) of the FD&C Act. There is no similar statutory requirement for an NDA applicant either under section 505(b)(1) or (b)(2) of the FD&C Act to demonstrate bioequivalence of its proposed product to another product. As a scientific matter, however, the same or a similar showing of the bioavailability of two products in the NDA context may be needed for the purposes of evaluating the safety or effectiveness of a product. For ease of the reader, we refer to such evaluations of the relative bioavailability for two or more products as an evaluation of bioequivalence in this guidance.

<sup>5</sup> For information on these types of studies, see FDA’s Drugs guidance Web page. See footnote #2 for information on accessing this Web page.

<sup>6</sup> Revisions to the March 2003 BA and BE Guidance include (1) expansion of the section on modified-release products, (2) addition of a section on concomitant administration of drug products and combination drug products, (3) addition of a section on alcoholic beverage effects on modified-release dosage forms, (4) addition of an endogenous substance section, (5) addition of a section on drug products with high intrasubject variability, and (6) removal of references to BE studies conducted for ANDAs. The guidance also makes other revisions for clarification.

<sup>7</sup> See footnote #2.

*Contains Nonbinding Recommendations*

54 BA assessment of formulations is a component of new drug development. The approaches of  
55 evaluating BA and BE discussed in this guidance are designed to aid FDA evaluation of the  
56 safety and effectiveness of a product that is the subject of an IND, NDA, or NDA supplement.  
57 In this endeavor, we use the totality of information available in the submission, which includes,  
58 among other things, information gathered using the principles of BE, exposure-response  
59 evaluations, and clinical trial results. The evaluation of BE in the generic drug context, by  
60 contrast, is used to support a determination that a generic product may be substituted for its  
61 reference listed drug, and involves consideration of different types of data permitted in an  
62 ANDA. Accordingly, the approaches discussed in this guidance may differ from similar  
63 discussions of BE in the ANDA BE Draft Guidance. For example, this NDA BA and BE Draft  
64 Guidance recommends assessment of the effect of food on BA using the approaches set forth in  
65 FDA’s 2002 guidance for industry on *Food-Effect Bioavailability and Fed Bioequivalence*  
66 *Studies* (the 2002 Food-Effect Guidance). Fasting BE studies generally are sufficient, given the  
67 totality of information we consider in evaluating INDs, NDAs, or NDA supplements. In  
68 contrast, we recommend in the ANDA BE Draft Guidance fed and fasting BE studies that will  
69 provide specific information to support a demonstration of BE under section 505(j) of the FD&C  
70 Act, and in turn, to support substitutability. Even though the ANDA BE Draft Guidance revises  
71 and replaces the parts of the 2002 Food-Effect Guidance pertaining to ANDAs and ANDA  
72 supplements, this NDA BA and BE Draft Guidance does not replace the 2002 Food-Effect  
73 Guidance relating to studies for INDs, NDAs, and NDA supplements.<sup>8</sup>

74  
75 **A. General**

76  
77 Studies to measure BA and/or establish BE of a product are important elements in support of  
78 INDs, NDAs, and NDA supplements. *Bioavailability* means the rate and extent to which the  
79 active ingredient or active moiety is absorbed from a drug product and becomes available at the  
80 site of action (21 CFR 320.1(a)). BA data provide an estimate of the fraction of the drug  
81 absorbed, as well as provide information related to the pharmacokinetics of the drug.

82  
83 *Bioequivalence* means the absence of a significant difference in the rate and extent to which the  
84 active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives  
85 become available at the site of drug action when administered at the same molar dose under  
86 similar conditions in an appropriately designed study (21 CFR 320.1(e)). Studies to establish  
87 BE between two products are important for certain formulation or manufacturing changes  
88 occurring during the drug development and postapproval stages. In BE studies, the exposure  
89 profile of a test drug product is compared to that of a reference drug product.

90  
91 **B. Bioavailability**

92  
93 BA for a given formulation provides an estimate of the relative fraction of the orally  
94 administered dose that is absorbed into the systemic circulation. BA for orally administered drug  
95 products can be documented by comparing a systemic exposure profile to that of a suitable  
96 reference product. A profile can be generated by measuring the concentration of active

---

<sup>8</sup> Accordingly, we are in the process of revising the 2002 Food-Effect Guidance.

*Contains Nonbinding Recommendations*

97 ingredients and/or active moieties over time and, when appropriate, active metabolites over time  
98 in samples collected from the systemic circulation. Systemic exposure profiles reflect both  
99 release of the drug substance from the drug product and a series of possible presystemic/systemic  
100 actions on the drug substance after its release from the drug product.

101  
102 FDA's regulations at 21 CFR 320.25 set forth guidelines for in vivo BA studies. As provided in  
103 this regulation, the reference product for BA studies should be a solution, suspension, or  
104 intravenous (IV) dosage form (21 CFR 320.25(d)(2) and (3)). The purpose of conducting a BA  
105 study with an oral solution as a reference is to assess the impact of formulation on BA.  
106 Conducting a BA study with an IV reference enables assessment of the impact of route of  
107 administration on BA and defines the absolute BA of the drug released from the drug product.

108  
109  
110 **C. Bioequivalence**

111  
112 As noted previously, both BA and BE focus on the release of a drug substance from a drug  
113 product and subsequent absorption into systemic circulation. As a result, we recommend that  
114 approaches to determining BE generally follow approaches similar to those used for BA.  
115 Demonstrating BE involves a more formal comparative test that uses specific references with  
116 specified criteria for comparisons and predetermined BE limits for such criteria.

117  
118 *1. Preapproval Changes*

119  
120 BE documentation can be useful during the IND period to compare (1) early and late  
121 clinical trial formulations; (2) formulations used in clinical trials and stability studies, if  
122 different; (3) clinical trial formulations and to-be-marketed drug products, if different;  
123 and (4) product strength equivalence, as appropriate. In each comparison, the new  
124 formulation, formulation produced by the new method of manufacture, or new strength is  
125 the candidate, or test product and the prior formulation, prior method of manufacture, or  
126 prior strength is the reference product. The decision to document BE during drug  
127 development is generally left to the judgment of the sponsor, using the principles of  
128 relevant guidances (in this guidance, see sections II.C.2, Postapproval Changes, and  
129 III.D, In Vitro Studies) to determine when changes in components, composition, and/or  
130 method of manufacture suggest that further in vitro and/or in vivo studies be performed.

131  
132 *2. Postapproval Changes*

133  
134 In the presence of certain major changes in components, composition, manufacturing site,  
135 and/or method of manufacture after approval, FDA recommends that in vivo BE be  
136 demonstrated for the drug product after the change in comparison to the drug product  
137 before the change. Under section 506A(c)(2) of the Federal Food, Drug, and Cosmetic  
138 Act (FD&C Act) (21 U.S.C. 356a(c)(2)), certain postapproval changes that require  
139 completion of studies must be submitted in a supplement and approved by FDA before  
140 distributing a drug product made with the change.

*Contains Nonbinding Recommendations*

142 Information on the types of recommended in vitro dissolution and in vivo BE studies for  
143 immediate-release and modified-release drug products approved as NDAs for specified  
144 postapproval changes is provided in the following FDA guidances:  
145

- 146 • *SUPAC-IR: Immediate Release Solid Oral Dosage Forms: Scale-Up and*  
147 *Postapproval Changes: Chemistry, Manufacturing, and Control; In Vitro*  
148 *Dissolution Testing, and In Vivo Bioequivalence Documentation*
- 149 • *SUPAC-MR: Modified Release Solid Oral Dosage Forms: Scale-Up and*  
150 *Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro*  
151 *Dissolution Testing, and In Vivo Bioequivalence Documentation*

152  
153 3. *BE Considerations*  
154

155 BE studies are usually conducted using a crossover design. For such studies, intrasubject  
156 variability should be considered when determining the study sample size. In cases when  
157 a parallel design is necessary to evaluate BE, consideration should be given to total  
158 variability, including intersubject variability instead of just intrasubject variability.  
159

160 A test product might fail to demonstrate bioequivalence because it has measures of rate  
161 and/or extent of absorption compared to the reference product outside acceptable higher  
162 or lower limits. For example, when the test product results in a systemic exposure that is  
163 significantly higher than that of the reference product, the concern is the typically limited  
164 experience from a safety standpoint for higher systemic concentrations. When the test  
165 product has a systemic exposure that is significantly lower than that of the reference  
166 product, the concern is potentially a lack of therapeutic efficacy of the test product.  
167 When the variability of the test product is greater than the reference product, the concern  
168 relates to both safety and efficacy, because it may suggest that the performance of the test  
169 product is not comparable to the reference product, and the test product may be too  
170 variable to be clinically useful.  
171

172 When BE is not demonstrated, the sponsor should demonstrate that the differences in rate  
173 and extent of absorption do not significantly affect the safety and efficacy based on  
174 available dose-response or concentration-response data. In the absence of this evidence,  
175 failure to demonstrate BE may suggest that the test product should be reformulated, or  
176 the method of manufacture for the test product should be changed, or additional safety or  
177 efficacy data may be needed for the test product. In some cases, conclusions of BE based  
178 on the peak drug concentration ( $C_{max}$ ) and area under the plasma concentration time curve  
179 (AUC) between the test product and the reference product may be insufficient to  
180 demonstrate that there is no difference in safety or efficacy if the systemic concentration-  
181 time profiles of the test product and the reference product are different (e.g., time to reach  
182 peak drug concentration ( $T_{max}$ ) is different). For example, differences in the shape of the  
183 systemic concentration profile between the test and reference products could imply that  
184 the test product may not produce the same clinical response as the reference product. In  
185 such cases, additional data analysis (e.g., partial AUCs), exposure-response evaluation, or  
186 clinical studies may be recommended to evaluate the BE of the two products.



*Contains Nonbinding Recommendations*

187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227

**III. METHODS TO DOCUMENT BA AND BE**

Under FDA’s regulations, applicants must use the most accurate, sensitive, and reproducible method available to demonstrate BA or BE of a product (21 CFR 320.24(a)). As noted in 21 CFR 320.24, several in vivo and in vitro methods can be used to measure BA and to establish BE. These include, in general order of preference, pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo BA (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. In addition, where in vivo data are appropriate to demonstrate BA, our regulations provide guidelines on specific types of in vivo BA studies (see 21 CFR 320.25 through 320.29). This guidance predominantly focuses on the use of PK studies to document BA or BE.

**A. Pharmacokinetic Studies**

*1. General Considerations*

FDA’s regulations generally define BA and BE in terms of rate and extent of absorption of the active ingredient or moiety to the site of action.<sup>9</sup> For in vivo studies, the regulations also provide for use of PK measures in an accessible biological matrix such as blood, plasma, and/or serum to indicate release of the drug substance from the drug product into the systemic circulation.<sup>10</sup> BA and BE frequently rely on PK measures such as AUC to assess extent of systemic exposure and  $C_{max}$  and  $T_{max}$  to assess rate of systemic absorption. PK-based comparisons to describe relative BA or make BE determinations are predicated on an understanding that measuring the active moiety or ingredient at the site of action is generally not possible and on an assumption that some relationship exists between the efficacy/safety and concentration of the active moiety and/or its important metabolite(s) in the systemic circulation. A typical study is conducted as a crossover study. The crossover design reduces variability caused by patient-specific factors, thereby increasing the ability to discern differences because of formulation.

*2. Pilot Study*

If the sponsor chooses, a pilot study in a small number of subjects can be carried out before proceeding with a full-scale BA or BE study. The pilot study can be used to validate analytical methodology, assess PK variability, determine sample size to achieve adequate power, optimize sample collection time intervals, and determine the length of the washout period needed between treatments. For example, for conventional immediate-release products, careful timing of initial samples may avoid a subsequent finding in a full-scale study that the first sample collection occurs after the  $C_{max}$ . For modified-release products, a pilot study can help determine the sampling schedule needed

---

<sup>9</sup> 21 CFR 320.1(a) and (e).  
<sup>10</sup> See, e.g., 21 CFR 320.24(b)(1)(i). If serial measurements of the drug or its metabolites in plasma, serum, or blood cannot be accomplished, then measurement of urinary excretion can be used.

*Contains Nonbinding Recommendations*

228 to assess lag time and dose dumping. The results of a pilot study can be used as the sole  
229 basis to document BA or BE provided the study's design and execution are suitable and a  
230 sufficient number of subjects have completed the study.

231

232 3. *Full-Scale Study*

233

234 General recommendations for a standard BA or BE study based on PK measurements are  
235 provided in Appendix A. Nonreplicate crossover study designs are recommended for BA  
236 and BE studies of immediate-release and modified-release dosage forms. However,  
237 sponsors and/or applicants have the option of using replicate designs for BE studies.

238 Replicate crossover designs are used to allow estimation of (1) within-subject variance  
239 for the reference product, or for both the test and reference products, and (2) the subject  
240 by formulation interaction variance component. This design accounts for the inter-  
241 occasion variability that may confound the interpretation of a BE study as compared to a  
242 non-replicate crossover approach. The recommended method of analysis for nonreplicate  
243 or replicate studies to evaluate BE is average BE, as discussed in section IV.

244 Recommendations for conducting and evaluating replicate study designs can be found in  
245 the FDA guidance for industry *Statistical Approaches to Establishing Bioequivalence*.

246

247 4. *Study Population*

248

249 Subjects recruited for BA or BE studies should be 18 years of age or older and capable of  
250 giving informed consent. In general, BA and BE studies should be conducted in healthy  
251 volunteers if the product can be safely administered to this population. A study in healthy  
252 volunteers is likely to produce less PK variability compared with that in patients with  
253 potentially confounding factors such as underlying and/or concomitant disease and  
254 concomitant medications. Male and female subjects should be enrolled in BA and BE  
255 studies unless there is a specific reason to exclude one sex. Such exclusions could be  
256 related to the drug product being indicated in only one sex or a greater potential for  
257 adverse reactions in one sex compared to the other. For example, oral contraceptives are  
258 evaluated in female subjects because the indication is specific to females. If a drug has  
259 the potential to be a teratogen, the drug product should be evaluated in male subjects.  
260 Female subjects enrolled in the study should not be pregnant at the beginning of the study  
261 and should not become pregnant during the study. In some instances (e.g., when safety  
262 considerations preclude use of healthy subjects), it may be necessary to evaluate BA and  
263 BE in patients for whom the drug product is intended. In this situation, sponsors and/or  
264 applicants should attempt to enroll patients whose disease process is expected to be stable  
265 for the duration of the study.

266

267 5. *Single-Dose and Multiple-Dose (Steady State) Testing*

268

269 This guidance generally recommends single-dose PK studies to assess BA and BE  
270 because they are generally more sensitive than steady-state studies in assessing rate and  
271 extent of release of the drug substance from the drug product into the systemic  
272 circulation.

*Contains Nonbinding Recommendations*

273  
274 FDA's regulations at 21 CFR 320.27 provide guidelines on the design of a multiple-dose  
275 in vivo BA study. This regulation also identifies instances in which multiple-dose BA  
276 studies may be required:

- 277  
278 i. There is a difference in the rate of absorption but not in the extent of absorption.  
279 ii. There is excessive variability in bioavailability from subject to subject.  
280 iii. The concentration of the active drug ingredient or therapeutic moiety, or its  
281 metabolite(s), in the blood resulting from a single dose is too low for accurate  
282 determination by the analytical method.  
283 iv. The drug product is an extended-release dosage form.<sup>11</sup>  
284

285 We recommend that if a multiple-dose study design is performed, appropriate dosage  
286 administration and sampling be carried out to document attainment of steady state.  
287

288 6. *Bioanalytical Methodology*  
289

290 We recommend that sponsors ensure that bioanalytical methods for BA and BE studies  
291 be accurate, precise, specific, sensitive, and reproducible. A separate FDA guidance,  
292 *Bioanalytical Method Validation*, is available to assist sponsors in validating  
293 bioanalytical methods.<sup>12</sup>  
294

295 7. *Administration Under Fasted/Fed Conditions*  
296

297 The BA or BE study should be conducted under fasting conditions (after an overnight fast  
298 of at least 10 hours) except when tolerability issues are anticipated with fasting. In these  
299 cases, we recommend that applicants conduct only a fed study. A separate FDA  
300 guidance, *Food-Effect Bioavailability and Fed Bioequivalence Studies* is available to  
301 assist sponsors.  
302

303 8. *Moieties to Be Measured*  
304

305 The active ingredient that is released from the dosage form or its active moiety and, when  
306 appropriate, its active metabolites<sup>13</sup> should be measured in biological fluids collected in  
307 BA studies.  
308

309 Measurement of the active ingredient or the active moiety, rather than metabolites, is  
310 generally recommended for BE studies because the concentration-time profile of the  
311 active ingredient or the active moiety is more sensitive to changes in formulation  
312 performance than that of the metabolite, which is more reflective of metabolite formation,  
313 distribution, and elimination. The following are instances when an active metabolite(s)  
314 should be measured.

---

<sup>11</sup> 21 CFR 320.27(a)(3).

<sup>12</sup> See also 21 CFR 320.29.

<sup>13</sup> See 21 CFR 320.24(b)(1)(i).

*Contains Nonbinding Recommendations*

- 315
- 316
- 317
- 318
- 319
- 320
- 321
- 322
- 323
- 324
- 325
- 326
- 327
- 328
- Measurement of a metabolite(s) is necessary when the active ingredient or the active moiety concentrations are too low to allow reliable analytical measurement in blood, plasma, or serum. In this case, the metabolite should be measured in lieu of the active ingredient or active moiety. We recommend that the confidence interval approach be applied to the metabolite data obtained from these studies.
  - Measurement of a metabolite(s) is necessary in addition to the active ingredient or active moiety if the metabolite is formed by presystemic metabolism and contributes meaningfully to efficacy and/or safety. The confidence interval approach should be used for all moieties measured. However, the BE criteria are only generally applied to the active ingredient or active moiety. Sponsors should contact the appropriate review division to determine which moieties should be measured.

329 9. *Pharmacokinetic Measures of Systemic Exposure*

330

331 This guidance recommends that systemic exposure measures be used to evaluate BA and

332 BE. Exposure measures are defined relative to peak, partial, and total portions of the

333 plasma, serum, or blood concentration-time profile, as describe here:

334

335 • Peak Exposure

336

337 We recommend that peak exposure be assessed by measuring the  $C_{\max}$  obtained directly

338 from the systemic drug concentration data without interpolation. The  $T_{\max}$  can provide

339 important information about the rate of absorption. The first point of a concentration-

340 time curve based on blood and/or plasma measurements is sometimes the highest

341 concentration, which raises a question about the measurement of true  $C_{\max}$  because of

342 insufficient early sampling times. A carefully conducted pilot study may help to avoid

343 this problem. Collection of an early time point between 5 and 15 minutes after dosing

344 followed by additional sample collections (e.g., two to five) in the first hour after dosing

345 may be sufficient to assess early peak concentrations. If this sampling approach is

346 followed, we consider the data to be adequate, even when the highest observed

347 concentration occurs at the first time point.

348

349 • Total Exposure (Extent of Absorption)

350

351 For single-dose studies, we recommend that the measurement of total exposure be:

352

- 353
- 354
- 355
- 356
- 357
- 358
- 359
- Area under the plasma, serum, or blood concentration time curve from time zero to time  $t$  ( $AUC_{0-t}$ ), where  $t$  is the last time point with a measurable concentration.
  - Area under the plasma, serum, or blood concentration time curve from time zero to time infinity ( $AUC_{0-\infty}$ ), where  $AUC_{0-\infty} = AUC_{0-t} + C_t/\lambda_z$ .  $C_t$  is the last measurable drug concentration and  $\lambda_z$  is the terminal or elimination rate constant calculated according to an appropriate method.

*Contains Nonbinding Recommendations*

360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401

- For drugs with a long half-life, truncated AUC can be used (see section VII.D, Long-Half-Life Drugs).

For steady-state studies, we recommend that the measurement of total exposure be the area under the plasma, serum, or blood concentration time curve from time zero to time tau over a dosing interval at steady state ( $AUC_{0-\tau}$ ), where tau is the length of the dosing interval.

- Partial Exposure

For orally administered drug products, BA and BE can generally be demonstrated by measurements of peak and total exposure. For certain classes of drugs and under certain circumstances (e.g., to assess onset of an analgesic effect), an evaluation of the partial exposure could be used to support the performance of different formulations by providing further evidence of therapeutic effect. This guidance recommends the use of partial AUC as a partial exposure measure. The time to truncate the partial area should be related to a clinically relevant PD measure. We also recommend that sufficient quantifiable samples be collected to allow adequate estimation of the partial area. For questions on the suitability of the PD measure or use of partial exposure in general, we recommend that sponsors and/or applicants consult the appropriate review division.

*10. Comparison of PK measures in BE studies*

An equivalence approach is recommended for BE comparisons. The recommended approach relies on (1) a criterion to allow the comparison, (2) a confidence interval for the criterion, and (3) a BE limit. Log-transformation of exposure measures before statistical analysis is recommended. This guidance recommends use of an average BE criterion to compare systemic exposure measures for replicate and nonreplicate BE studies of both immediate- and modified-release products. For additional information on data analysis, refer to Appendix A and to the FDA guidance for industry on *Statistical Approaches to Establishing Bioequivalence*.

**B. Other Approaches to Support BA/BE**

In certain circumstances, other approaches are recommended to support a demonstration of BA/BE. Below are some general considerations regarding these other approaches. Sponsors should consult FDA’s guidances for industry for additional information on these methods as well.<sup>14</sup>

- 1. In Vitro Tests Predictive of Human In Vivo BA*
  - 1.

---

<sup>14</sup> See footnote 2.

*Contains Nonbinding Recommendations*

402 In vitro-in vivo correlation (IVIVC) is an approach to describe the relationship  
403 between an in vitro attribute of a dosage form (e.g., the rate or extent of drug  
404 release) and a relevant in vivo response (e.g., plasma drug concentration or  
405 amount of drug absorbed). This model relationship facilitates the rational  
406 development and evaluation of extended-release dosage forms. Once an IVIVC is  
407 validated, the in vitro test serves as a surrogate for BA and/or BE testing, as well  
408 as a tool for formulation screening and setting of the dissolution/drug-release  
409 acceptance criteria.

410  
411 Specifically, in vitro dissolution/drug-release characterization is encouraged for  
412 all extended-release product formulations investigated (including prototype  
413 formulations), particularly if in vivo absorption characteristics are being defined  
414 for the different product formulations. Such efforts may enable the establishment  
415 of an IVIVC. When an IVIVC or association is established (21 CFR  
416 320.24(b)(1)(ii)), the in vitro test can serve not only as a quality control  
417 specification for the manufacturing process, but also as an indicator of how the  
418 product will perform in vivo.

419  
420 Additional information on the development and validation of an IVIVC can be  
421 found in the FDA guidance for industry *Extended Release Oral Dosage Forms:  
422 Development, Evaluation, and Application of In Vitro/In Vivo Correlations*.

423  
424 2. *Pharmacodynamic Studies*

425  
426 PD studies are not recommended for orally administered drug products when the  
427 drug is absorbed into systemic circulation and a PK approach can be used to  
428 assess systemic exposure and evaluate BA or BE. PK endpoints are preferred  
429 because they are generally the most accurate, sensitive, and reproducible  
430 approach. However, in instances where a PK endpoint is not possible, a well-  
431 justified PD endpoint can be used to demonstrate BA or BE.

432  
433 3. *Comparative Clinical Studies*

434  
435 Clinical endpoints can be used in limited circumstances, for example, for orally  
436 administered drug products when the measurement of the active ingredients or  
437 active moieties in an accessible biological fluid (PK approach) or PD approach is  
438 not possible. Because these circumstances do not occur very often, use of this  
439 approach is expected to be rare.

440  
441 4. *In Vitro Studies*

442  
443 Under certain circumstances, BA and BE can be evaluated using in vitro  
444 approaches (e.g., dissolution/drug-release testing) during the preapproval and  
445 postapproval phases (see 21 CFR 320.24(b)(5) and (6)). For example, orally  
446 administered drugs that are highly soluble and highly permeable, and for which

*Contains Nonbinding Recommendations*

447 the drug product is rapidly dissolving, documentation of BE using an in vitro  
448 approach (dissolution/drug-release studies) may be appropriate based on the  
449 Biopharmaceutics Classification System.<sup>15</sup>

450  
451 The following FDA guidances provide recommendations on the development of  
452 dissolution methodology, setting specifications, and the regulatory applications of  
453 dissolution testing:

- 454
- 455 • *Dissolution Testing of Immediate-Release Solid Oral Dosage Forms*
- 456
- 457 • *Extended-Release Oral Dosage Forms: Development, Evaluation, and*  
458 *Application of In Vitro/In Vivo Correlations*
- 459

460 In addition, we recommend that sponsors consult other FDA guidances for  
461 additional information on when in vitro data may be appropriate to demonstrate  
462 BA or BE of a product.

463

#### 464 **IV. DOCUMENTING BA AND BE FOR VARIOUS DOSAGE FORMS**

465

466 This section summarizes the recommendations for documenting BA and BE studies based on the  
467 specific dosage forms and whether these evaluations occur preapproval or postapproval.

468

##### 469 **A. Solutions and Other Solubilized Dosage Forms**

470

471 For oral solutions, elixirs, syrups, tinctures, or other solubilized forms, in vivo BA and/or BE are  
472 generally self-evident and a requirement of in vivo data for a product may be waived (21 CFR  
473 320.22(b)(3)). In such instances, the applicant would be deemed to have complied with and  
474 fulfilled any requirement for in vivo data.<sup>16</sup> Although a comparative study is not necessary,  
475 characterization of the pharmacokinetics of the drug is required (21 CFR 314.50(d)(3)). In  
476 addition, in vivo BE studies that compare different solution formulations are waived based on the  
477 assumptions that release of drug substance from the drug product is self-evident and that the  
478 solutions do not contain any excipients that significantly affect drug absorption. However, there  
479 are certain excipients that may alter the BA (e.g., sorbitol may reduce the BA of drugs, and  
480 vitamin E may enhance the BA) in amounts sometimes used in oral liquid dosage forms. In this  
481 case, evaluation of in vivo BA and/or BE may be required.

482

##### 483 **B. Immediate-Release Products**

484

485 Included in this discussion are capsules, tablets (including conventional, buccal, chewable, orally  
486 disintegrating, and sublingual dosage forms), and suspensions.

---

<sup>15</sup> See the FDA guidance for industry on *Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System*. This document provides complementary information on the Biopharmaceutics Classification System (BCS).

<sup>16</sup> See 21 CFR 320.22(b)(3).

*Contains Nonbinding Recommendations*

487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529

1. *Preapproval Changes*

For BA and BE studies, we recommend a single-dose, fasting study be performed. Under certain circumstances, multiple-dose BA studies (see section III.A.5) and/or food effect studies may be necessary (See the FDA guidance for industry *Food-Effect Bioavailability and Fed Bioequivalence*). Unconventional dosage forms (buccal, chewable, orally disintegrating, and sublingual dosage forms) should be administered according to intended label use/instructions. In addition, a BA study may be needed with the unconventional dosage form swallowed intact to assess the impact of accidental swallowing of the intact product. Sampling should adequately capture the  $T_{max}$  and  $C_{max}$  in addition to total exposure.

We recommend that in vitro dissolution be evaluated for all orally administered products. In vitro dissolution test conditions could be the same or different for unconventional compared to conventional dosage forms. If differences in dissolution data exist, they should be discussed with the appropriate review division.

2. *Postapproval Changes*

Information on the types of in vitro dissolution and in vivo BE studies needed for approved immediate-release drug products when postapproval changes are made is provided in an FDA guidance for industry entitled *SUPAC-IR: Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation*. We recommend that for postapproval changes, the in vitro or in vivo comparison be made between the post-change and pre-change products.

**C. Modified-Release Products**

Modified-release (MR) products include extended-release (controlled-release, sustained-release)<sup>17</sup> and delayed-release products.

Extended-release (ER) products are dosage forms that are designed to extend or prolong the release of active ingredient or active moiety from the drug product and may allow a reduction in dosing frequency as compared to when the drug is administered in an immediate-release (IR) dosage form. These drug products can be developed to reduce fluctuations in plasma concentrations when compared to an IR product. ER products can be capsules, tablets, granules, pellets, or suspensions.

Delayed-release (DR) drug products are dosage forms that release active ingredient or active moiety at a time later than immediately after administration (i.e., these drug products exhibit a lag time in quantifiable plasma concentrations). Typically, coatings (e.g., enteric coatings) are

---

<sup>17</sup> For the purpose of this guidance, the terms *extended*, *controlled*, and *sustained* are used interchangeably.



*Contains Nonbinding Recommendations*

530 used to delay the release of the drug substance until the dosage form has passed through the  
531 acidic medium of the stomach. Generally, DR products are treated as IR products. However, if  
532 the DR product has complex release characteristics, the relevant review division should be  
533 contacted for additional guidance.

534

535 If the drug product is an ER product, the following recommendations apply.

536

537 *1. Preapproval: BA and BE Studies*

538

539 FDA’s regulations at 21 CFR 320.25(f) address the purpose of a BA study for an  
540 extended-release product, which is to determine if certain delineated conditions are met.<sup>18</sup>  
541 This regulation also provides that “the reference material(s) for such a bioavailability  
542 study shall be chosen to permit an appropriate scientific evaluation of the extended  
543 release claims made for the drug product.”<sup>19</sup> Appropriate reference products may include  
544 (1) a solution or suspension of the active drug ingredient or therapeutic moiety, (2) a  
545 currently marketed non-controlled-release drug product containing the same active drug  
546 ingredient or therapeutic moiety and administered according to the dosage  
547 recommendations in the labeling of the non-controlled release drug product, and (3) a  
548 currently marketed ER drug product subject to an approved full NDA containing the  
549 same active drug ingredient or therapeutic moiety and administered according to the  
550 dosage recommendations in the labeling of currently marketed ER product.<sup>20</sup>

551

552 In general, the PK profile of the ER product may not match that of the approved IR  
553 product (e.g.,  $T_{max}$  is different) or, in some cases, to another ER product. In such a case,  
554 establishing similar PK profiles using  $C_{max}$  and AUC may not be sufficient to show that  
555 the ER product is bioequivalent to the IR product. Thus, additional safety or efficacy  
556 studies or PK/PD assessments may be recommended. This guidance recommends that the  
557 following BA studies and food effect BA studies be conducted for an ER drug product  
558 submitted as an NDA for the scenarios described below:

559

560 New ER formulation comparison to an already-approved IR product

561

- 562 • For drugs with linear pharmacokinetics over the therapeutic dose range: A fasting  
563 study should be conducted comparing the ER product administered as a single  
564 dose at the highest strength to the IR reference administered over the least  
565 common time interval to achieve equivalent total dose as for the ER product.<sup>21</sup> If

---

<sup>18</sup> 21 CFR 320.25(f)(1).

<sup>19</sup> 21 CFR 320.25(f)(2).

<sup>20</sup> 21 CFR 320.25(f)(2)(i), (ii), and (iv). We recommend that a sponsor seeking to use as a reference product “a currently marketed extended release drug product subject to an approved full new drug application containing the same active drug ingredient or therapeutic moiety and administered according to the dosage recommendations in the labeling proposed for the extended release drug product,” under 21 CFR 320.25(f)(2)(iii), consult with the Agency before commencing such a study.

<sup>21</sup> For example, when a 150-milligram (mg) ER product administered once daily (QD) is being developed that gives an approved 50-mg IR reference product administered three times a day (TID) or a 75-mg product administered two times a day (BID), a comparison of the 150-mg ER product administered as a single dose could be compared to

*Draft — Not for Implementation*

*Contains Nonbinding Recommendations*

566 for safety reasons the highest strength cannot be used, a lower strength may be  
567 acceptable.

- 568
- 569 • For drugs with nonlinear pharmacokinetics over the therapeutic dose range: At a  
570 minimum, a single dose of the highest and lowest strengths of the ER product  
571 should be compared to their corresponding IR references administered over the  
572 ER dosing interval. If the relative BA of intermediate ER strengths cannot be  
573 inferred based on the above studies, a single-dose fasting study for the  
574 intermediate strength(s) of the ER product should be compared to the  
575 corresponding IR reference administered over the ER dosing interval.  
576
  - 577 • When the ER strengths are not proportionally similar in composition, a single-  
578 dose fasting dosage strength equivalence assessment study<sup>22</sup> or a dosage strength  
579 proportionality study<sup>23</sup> for the ER product should be conducted.  
580
  - 581 • A single-dose food-effect study should be conducted on the highest ER strength  
582 (see the 2002 Food-Effect Guidance).  
583
  - 584 • A steady state study should be conducted on the highest strength of the ER  
585 product compared to an approved IR reference dosed to achieve equivalent total  
586 dose as for the ER product.  
587

588 New ER product (ER<sub>new</sub>) comparison to an approved ER product (ER<sub>old</sub>) with a different  
589 dosing interval (i.e., where ER<sub>new</sub> and ER<sub>old</sub> have unequal dosing intervals)  
590

- 591 • The recommendations are the same as outlined in the previous section  
592 (Development of a new ER formulation given an already approved IR product)  
593 except for the choice of the reference product. In this case, the reference product  
594 could be either the approved ER<sub>old</sub> or IR product.  
595

596 New ER product (ER<sub>new</sub>) comparison to an approved ER product (ER<sub>old</sub>) with the same  
597 dosing interval  
598

- 599 • A single-dose fasting BE study on the highest strength of the ER<sub>new</sub> product  
600 compared to the ER<sub>old</sub> product. If ER<sub>new</sub> and ER<sub>old</sub> are of different strength, then

either the 50-mg IR reference product administered TID or 75-mg IR reference product administered BID. In this case, the least common time interval is 24 hours.

<sup>22</sup> If three strengths, 10, 25, and 50 mg, are being developed for a new ER dosage form, the dosage strength equivalence study should be conducted using 5×10 mg, 2×25 mg, and 1×50 mg to achieve constancy of dose.

<sup>23</sup> If three strengths, 10, 25, and 50 mg, are being developed for a new ER dosage form, the dosage strength proportionality study should be conducted using 1×10 mg, 1×25 mg, and 1×50 mg to achieve constancy of dose and the dosage strength proportionality study should be conducted using 1×10 mg, 1×25 mg, and 1×50 mg.

*Contains Nonbinding Recommendations*

601 comparison of ER<sub>new</sub> versus ER<sub>old</sub> should be made based on dose using the highest  
602 strengths.

- 603
- 604 • A single-dose, food-effect study should be conducted on the highest ER<sub>new</sub>  
605 strength.
  - 606
  - 607 • When the ER<sub>new</sub> strengths are not proportionally similar in composition, a single-  
608 dose fasting dosage strength equivalence assessment study or a dosage strength  
609 proportionality study<sup>24</sup> for the ER<sub>new</sub> product should be conducted.
  - 610
  - 611 • In some cases, BE between the new and old ER products may not be sufficient to  
612 ensure that there is no difference in safety or efficacy if the PK profiles of the two  
613 ER products do not match (e.g., T<sub>max</sub> is different). Additional data analysis or  
614 clinical studies may be needed to ensure that the two products are clinically  
615 equivalent.
  - 616

617 2. *Postapproval Changes*

618

619 Information on the types of in vitro dissolution and in vivo BE studies for ER drug  
620 products approved in the presence of specific postapproval changes are provided in an  
621 FDA guidance for industry *SUPAC-MR: Modified Release Solid Oral Dosage Forms:  
622 Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro  
623 Dissolution Testing, and In Vivo Bioequivalence Documentation*. We recommend that  
624 for postapproval changes, the in vitro or in vivo comparison be made between the post-  
625 change and pre-change products.

626

627 **D. Batch Size**

628

629 For pivotal BE studies, the test batch should be representative of the production batches.  
630 Therefore, the size of the test batch should be at least 10% of the planned production batch size,  
631 or a minimum of 100,000 units, whichever is larger.

632

633 **V. ADDITIONAL INFORMATION ON IN VITRO APPROACHES**

634

635 **A. In Vitro Studies Conducted in Support of a Waiver of an In Vivo BA or BE**  
636 **Data Requirement**

637

638 As discussed above, FDA’s regulations contemplate that if in vivo BA or BE data are required  
639 for a product, a sponsor may seek a waiver of that requirement under certain circumstances.<sup>25</sup>

---

<sup>24</sup> 21 CFR 320.21(b) (giving applicants the option of submitting information that “would permit FDA to waive the submission of evidence demonstrating in vivo bioequivalence”) and 320.21(f) (requiring that the information submitted in support of a waiver request “shall meet the criteria set forth in § 320.22”).

<sup>25</sup> 21 CFR 320.21(b) (giving applicants the option of submitting information that “would permit FDA to waive the submission of evidence demonstrating in vivo bioequivalence”) & 320.21(f) (requiring that the information submitted in support of a waiver request “shall meet the criteria set forth in § 320.22.”)

*Contains Nonbinding Recommendations*

640 For example, in some instances, in vivo BA or BE is self-evident based on certain characteristics  
641 of the drug product (21 CFR 320.22(b)), and therefore, any in vivo data requirement has been  
642 deemed to have been met. In other delineated circumstances, an in vivo BA or BE data  
643 requirement may be waived, and in vitro data may be accepted in lieu of in vivo data (21 CFR  
644 320.22(d)). For example, an in vivo data requirement may be waived for different strengths of  
645 an immediate-release drug product under 21 CFR 320.22(d)(2) when (1) the drug product is in  
646 the same dosage form, but in a different strength; (2) this different strength is proportionally  
647 similar in its active and inactive ingredients to another drug product for which the same  
648 manufacturer has obtained approval; and (3) the new strength meets an appropriate in vitro test  
649 as outlined in the regulation.<sup>26</sup> In addition, for waiving higher strengths, linearity of the  
650 pharmacokinetics over the therapeutic dose range should be demonstrated.

651  
652 This guidance defines *proportionally similar* in the following ways:

- 653  
654 • All active and inactive ingredients are in exactly the same proportion between different  
655 strengths (e.g., a tablet of 50-mg strength has all the inactive ingredients, exactly half that  
656 of a tablet of 100-mg strength, and twice that of a tablet of 25-mg strength).
- 657  
658 • For high-potency drug substances (where the amount of active drug substance in the  
659 dosage form is relatively low), (1) the total weight of the dosage form remains nearly the  
660 same for all strengths (within  $\pm 10\%$  of the total weight of the strength on which a BE  
661 was performed), (2) the same inactive ingredients are used for all strengths, and (3) the  
662 change in any strength is obtained by altering the amount of the active ingredients and  
663 one or more of the inactive ingredients.
- 664  
665 • Bilayer tablets are considered to be one formulation even though they consist of two  
666 separate layers with different compositions. In assessing the proportional similarity of  
667 the different strengths, all components of both layers should be proportionally similar.  
668 The fact that only one layer is proportionally similar and the other is not clearly indicates  
669 that the products (whole tablet) are not proportionally similar. This is relevant because  
670 there can be interactions between the different tablet layers, which can differ across  
671 different strengths because of the different size of the layers and the varying amounts of  
672 excipients present in each layer.

673  
674 Exceptions to the above definitions may be possible if adequate justification is provided and  
675 discussed with the appropriate review division.

676  
677 **B. In Vitro Studies Conducted in Support of Demonstrating BA or BE**

678  
<sup>26</sup> See also 21 CFR 322.22(d)(3) and (4) for additional bases for waiver. Also, FDA, for good cause, may waive a requirement for the submission of evidence of in vivo bioavailability or bioequivalence if waiver is compatible with the protection of the public health. For full NDAs, FDA may defer a requirement for the submission of evidence of in vivo bioavailability if deferral is compatible with the protection of the public health (21 CFR 320.22(e)).

*Contains Nonbinding Recommendations*

679 FDA may determine that in vitro data are the most accurate, sensitive, and reproducible method  
680 to demonstrate BA or BE in other contexts (21 CFR 320.24(b)(5) and (6)).<sup>27</sup> Below we provide  
681 additional guidance on the conduct of such studies.

682  
683 1. *Immediate-Release Formulations (Capsules, Tablets, and Suspensions)*

684  
685 In vitro data can be used to compare formulations of drug products under certain  
686 circumstances. If an applicant seeks to demonstrate the BA or BE of immediate-release  
687 formulations for capsules, tablets, and suspensions using in vitro data, FDA recommends  
688 that sponsors generate dissolution profiles for all strengths using an appropriate  
689 dissolution method. If the dissolution results indicate that the dissolution characteristics  
690 of the product are not dependent on the pH and product strength, dissolution profiles in  
691 one medium are usually sufficient to support demonstrating BE. Otherwise, dissolution  
692 data in at least three media (e.g., pH 1.2, 4.5, and 6.8) are recommended. The  $f_2$  test  
693 should be used to compare profiles from the different strengths of the product (see FDA  
694 guidance for industry, *Dissolution Testing of Immediate Release Solid Oral Dosage*  
695 *Forms*). An  $f_2$  value  $\geq 50$  indicates a sufficiently similar dissolution profile to support a  
696 biowaiver. For an  $f_2$  value  $< 50$ , discussion with the appropriate review division is  
697 recommended to determine whether an in vivo study is needed. The  $f_2$  approach is not  
698 suitable for rapidly dissolving drug products (e.g.,  $\geq 85\%$  dissolved in 15 minutes or less).

699  
700 • *Over-encapsulation of clinical trial formulations*

701  
702 During the course of drug development, sponsors sometimes have to blind the  
703 formulations that they use in the clinical trials. In certain situations, the only difference  
704 between the to-be-marketed and clinical trial formulations is that the dosage form is put  
705 into a capsule. This over-encapsulation is done mainly for blinding purposes. It may be  
706 possible to support bioequivalence of the to-be-marketed and clinical trial formulations  
707 using in vitro data only, provided that no other excipients are added to the capsule and the  
708 dissolution profiles are comparable in three media: pH 1.2, pH 4.5 and pH 6.8.

709  
710 • *Scale-up and postapproval changes*

711  
712 Certain formulation changes in components and composition, scale-up, manufacturing  
713 site, manufacturing process, or equipment can be made postapproval. Depending on the  
714 possible impact of the manufacturing change on the release of the active ingredient from  
715 the formulation and its BA, certain manufacturing changes for IR products can be  
716 approved based solely on similarity of the dissolution profiles between the postchange  
717 and prechange formulations. Information on recommendations for using in vitro  
718 dissolution and in vivo BE studies for immediate-release drug products in such  
719 circumstances is provided in FDA's guidance for industry on *SUPAC IR: Immediate-*  
720 *Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry,*  
721 *Manufacturing, and Controls; In Vitro Dissolution Testing, and In Vivo Bioequivalence*

---

<sup>27</sup> In such instances, no waiver under 21 CFR 320.21 and 320.22 is necessary.

*Contains Nonbinding Recommendations*

722 *Documentation.* The same principles described in the guidance can be applied to  
723 pre-approval changes in which the to-be-marketed formulation differs from the clinical  
724 trial formulation.

725  
726 2. *Modified-Release Formulations*

727  
728 The use of in vitro data may be acceptable for modified-release drug products for which  
729 specific postapproval changes are sought is delineated in the FDA guidance for industry  
730 *SUPAC-MR: Modified Release Solid Oral Dosage Forms: Scale-Up and Postapproval*  
731 *Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing, and In*  
732 *Vivo Bioequivalence Documentation.* The same principles described in the guidance may  
733 also apply to preapproval changes. Additional considerations for use of in vitro data are  
734 described below.

735  
736 • *Beaded capsules: lower/higher strength*

737  
738 For ER beaded capsules where the strength differs only in the number of beads  
739 containing the active moiety, a single-dose, fasting BA or BE study, as appropriate,  
740 should be carried out on the highest strength. In vivo BA or BE of one or more lower  
741 strengths can be demonstrated based on dissolution profile comparisons, with an in vivo  
742 BA or BE study only on the highest strength (unless safety reasons preclude the  
743 administration of the highest strength to healthy volunteers). The dissolution profiles for  
744 each strength should be generated using the recommended dissolution method. If the  
745 dissolution method has not been finalized, dissolution profiles should be generated in at  
746 least three media (e.g., pH 1.2, 4.5, and 6.8). In vivo BE studies for higher strengths may  
747 not be necessary based on (1) clinical safety and/or efficacy data on the proposed dose  
748 and the need for the higher strength, (2) linearity of pharmacokinetics over the  
749 therapeutic dose range, and (3) the same dissolution procedures being used for all  
750 strengths with similar dissolution results. The  $f_2$  test can be used to demonstrate similar  
751 profiles among the different strengths of the product.

752  
753 • *MR dosage forms: lower strength*

754  
755 For MR dosage forms, when the drug product is in the same dosage form but in a  
756 different strength and when (1) the drug exhibits linear pharmacokinetics, (2) the various  
757 strengths are proportionally similar in their active and inactive ingredients<sup>28</sup> and (3) the  
758 drug-release mechanism is the same, an in vivo BA or BE determination of one or more  
759 lower strengths can be demonstrated based on dissolution profile comparisons, with an in  
760 vivo BA or BE study only on the highest strength. The dissolution profiles for each  
761 strength should be generated using the recommended dissolution method. If the  
762 dissolution method has not been finalized, dissolution profiles should be generated in at

---

<sup>28</sup> If the formulations of all the strengths are not compositionally proportional, in vitro data can be submitted for the middle strength(s) if the following data are acceptable: (1) BA or BE data, as appropriate, for both the highest and the lowest strengths, and (2) in vitro multimedia dissolution comparison profiles using  $f_2$  evaluation.

*Contains Nonbinding Recommendations*

763 least three media (e.g., pH 1.2, pH 4.5, and pH 6.8). The dissolution profile should be  
764 generated on the test and reference products of all strengths using the same dissolution  
765 test conditions.

766

767 **VI. SPECIAL TOPICS**

768

769 **A. Alcoholic Beverage Effects on MR Drug Products**

770

771 The consumption of alcoholic beverages may affect the release of a drug substance from an MR  
772 formulation. The formulation may lose its MR characteristics, leading to more rapid drug release  
773 and altered systemic exposure. This more rapid drug release may have deleterious effects on the  
774 drug's safety and/or efficacy.

775

776 In vitro assessments of the drug release from the drug product using media with various alcohol  
777 concentrations should be conducted. Based on the results of the in vitro assessments, an in vivo  
778 BA study of the drug product when administered with alcohol may be needed.

779

780 **B. Enantiomers versus Racemates**

781

782 During development of a racemic drug product, the racemate should be measured in BA studies.  
783 It may also be important to measure the individual enantiomers of the racemate to characterize  
784 the pharmacokinetics of the enantiomers. For the development of a specific enantiomer, chiral  
785 inversion should be assessed.

786

787 Measurement of the racemate using an achiral assay is recommended for BE studies.

788 Measurement of individual enantiomers in BE studies is recommended only when all of the  
789 following conditions are met: (1) the enantiomers exhibit different PD characteristics, (2) the  
790 enantiomers exhibit different PK characteristics, (3) primary efficacy and safety activity resides  
791 with the minor enantiomer, and (4) nonlinear absorption is present (as expressed by a change in  
792 the enantiomer concentration ratio with change in the input rate of the drug) for at least one of  
793 the enantiomers. In such cases, we recommend that BE criteria be applied to the enantiomers  
794 separately.

795

796 **C. Drug Products With Complex Mixtures as the Active Ingredients**

797

798 Certain drug products may contain complex drug substances (i.e., active moieties or active  
799 ingredients that are mixtures of multiple synthetic and/or natural source components). Some or  
800 all of the components of these complex drug substances may not be fully characterized with  
801 regard to chemical structure and/or biological activity. Quantification of all active or potentially  
802 active components in BA and BE studies may not be possible. In such cases, we recommend  
803 that BA and BE studies be based on a select number of components. Criteria for component  
804 selection typically include the amount of the moiety in the dosage form, plasma or blood levels  
805 of the moiety, and biological activity of the moiety. When PK approaches are infeasible to  
806 assess rate and extent of absorption of a drug substance from a drug product, PD, clinical, or in  
807 vitro approaches may be appropriate.

*Contains Nonbinding Recommendations*

808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852

**D. Long-Half-Life Drugs**

In a BA or PK study involving an IR oral product with a long half-life ( $\geq 24$  hours), adequate characterization of the half-life should include blood sampling over a long period of time. For BA or BE determination of a drug product containing a drug with a long half-life, a nonreplicate, single-dose, crossover study can be conducted, provided an adequate washout period is used. If the crossover study is problematic, a study with a parallel design can be used. For either a crossover or parallel study, we recommend that the sample collection time be adequate to ensure completion of gastrointestinal transit (approximately 2 to 3 days) of the drug product and absorption of the drug substance.  $C_{\max}$  and a suitably truncated AUC can be used to characterize peak and total drug exposure, respectively. For drugs that demonstrate low intrasubject variability in distribution and clearance, a truncated AUC (e.g.,  $AUC_{0-72 \text{ hr}}$ ) can be used in place of  $AUC_{0-t}$  or  $AUC_{0-\infty}$ . For drugs that demonstrate high intrasubject variability in distribution and clearance, AUC truncation should not be used. In such cases, we recommend that sponsors and/or applicants consult the appropriate review division.

**E. Orally Administered Drugs Intended for Local Action**

Documentation of BA and BE when the drug substance produces its effects by local action in the gastrointestinal tract can be achieved either by using pharmacokinetics, an acceptable PD end point, clinical efficacy and safety studies, and/or suitably designed and validated in vitro studies, as appropriate. For such cases, we recommend that sponsors and/or applicants consult the appropriate review division. Additional safety studies may also be recommended to characterize the local safety of the product. The in vitro studies should reflect important clinical effects or should be more sensitive to changes in product performance compared to a clinical study. To ensure comparable safety, additional studies with and without food may help to understand the degree of systemic exposure that occurs following administration of a drug product intended for local action in the gastrointestinal tract.

**F. Combination/Coadministered Drug Products**

Two or more active ingredients can be formulated as a single drug product, which is referred to as a combination drug product. Generally, the purpose of an in vivo BA study involving a combination drug product is to compare the rate and extent of absorption of each active drug ingredient or therapeutic moiety in the combination drug product to the rate and extent of absorption of each active drug ingredient or therapeutic moiety administered concurrently in separate single-ingredient preparations (21 CFR 320.25(g)).

For the purpose of defining BA or determining BE when required, this guidance recommends that the following studies be conducted for a combination drug product:

- A two-treatment, single-dose, fasting study of the combination drug product versus single-ingredient drug products administered concurrently as a single treatment or an approved combination product containing the same active ingredients. This study should



*Contains Nonbinding Recommendations*

853 use the highest strength of the combination product with matching doses of individual  
854 drug products.

- 855
- 856 • Certain alternative study designs may also be acceptable depending on the specific  
857 situation. For instance, in the case of a combination product consisting of two  
858 components, a three-treatment study design comparing the combination drug product  
859 versus single-ingredient drug products administered separately may be appropriate.  
860
  - 861 • A single-dose, food-effect study on the combination drug product.  
862

863 BE studies for the combination product should include the measurement of systemic  
864 concentrations of each active ingredient. The confidence interval approach should be applied to  
865 each measured entity of the combination drug product and its reference product.  
866

867 In specific cases, drug products are given in combination (not co-formulated) with the objective  
868 of increasing the exposure of one of the drugs (subject drug). The second drug is not intended to  
869 have a therapeutic effect and is given only to increase the systemic exposure of the subject drug.  
870 When both the subject and second drug are new molecular entities, the BA of each should be  
871 assessed separately. If a BE study is needed for the subject drug for any reason, the subject drug  
872 should be administered with the second drug for both test and reference products. The  
873 corresponding PK results, including confidence intervals for BE criteria, should be applied to the  
874 subject drug. It is not necessary to measure the concentrations of the second drug. BE studies  
875 that are needed for the second drug should be conducted only with the second drug; the subject  
876 drug is not dosed with the second drug. When the combination includes a new molecular entity  
877 and an approved product, only the BA of the new molecular entity should be assessed. It is  
878 assumed that the BA of the approved product has been previously evaluated.  
879

880 **G. Endogenous Substances**  
881

882 Drug products can be developed that contain compounds that are endogenous to humans (e.g.,  
883 testosterone). When the endogenous compounds are identical to the drug that is being  
884 administered, determining the amount of drug released from the dosage form and absorbed by  
885 each subject is difficult. In most cases, it is important to measure and approximate the baseline  
886 endogenous levels of the compound in blood (plasma) and subtract these levels from the total  
887 concentrations measured from each subject after the drug product is administered. In this way,  
888 an estimate of actual drug availability from the drug product can be achieved, and therefore BA  
889 and BE can be assessed. Endogenous substances may have homeostatic processes that affect  
890 their production and therefore impact their systemic concentrations. To reduce the complication  
891 of these homeostatic processes and to potentially avoid the need for baseline correction, an  
892 alternative approach might be to enroll patients in BA and BE studies with low or no production  
893 of the endogenous substances instead of healthy volunteers.  
894

895 Baseline concentrations of the endogenous substance produced by the body are measured in the  
896 time period prior to study drug administration. Depending on the proposed indication,  
897 subtraction of the time-averaged baseline or time-matched baseline from the post-dose

*Contains Nonbinding Recommendations*

898 concentration for each subject may be recommended. When the endogenous levels are  
899 influenced by diet, strict control of the dietary intake of the compound prior to and during the  
900 study may also be appropriate. To achieve a stable baseline, subjects should be housed at the  
901 clinic for a sufficient time prior to the study and served standardized meals with similar content  
902 of the compound to that of the meals served on the PK sampling day.

903  
904 In either case, baseline concentrations should be determined for each dosing period, and baseline  
905 corrections should be period-specific. If a negative plasma concentration value results after  
906 baseline correction, this should be set to 0 prior to calculating the baseline-corrected AUC.  
907 Pharmacokinetics and statistical analysis should be performed on both uncorrected and corrected  
908 data as appropriate. Because of the complexities associated with endogenous compounds, we  
909 recommend that sponsors and/or applicants contact the appropriate review division for additional  
910 guidance.

911  
912 **H. Drug Products With High Intrasubject Variability**

913  
914 In addition to the traditional approach and the use of average BE using replicate designs, the use  
915 of a reference-scaled BE approach using a replicate design can be considered. This approach  
916 should be reserved for drugs that demonstrate a high intrasubject variability ( $\geq 30\%$ ). The  
917 reference-scaled average BE approach adjusts the BE limits of highly variable drugs by scaling  
918 to the within-subject variability of the reference product in the study and imposes a limit of 0.8 to  
919 1.25 on the geometric mean ratio.<sup>29</sup> The appropriate review division should be consulted when  
920 planning the use of the reference-scaled BE approach.

921  
922

---

<sup>29</sup> For general principles of the reference-scaled approach, refer to Davit B, Conner D. Reference-Scaled Average Bioequivalence Approach. In: Kanfer I, Shargel L, Eds. *Generic Drug Product Development – International Regulatory Requirements For Bioequivalence*. Informa Healthcare, 2010:271-272.

**APPENDIX A: GENERAL STUDY DESIGN AND DATA HANDLING**

923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966

The following general approaches are recommended, recognizing that the elements can be adjusted for certain drug substances and drug products.

**Study conduct**

- The BA or BE study should be conducted under fasting conditions (after an overnight fast of at least 10 hours). If the BA or BE study needs to be conducted with food, a separate FDA guidance *Food-Effect Bioavailability and Fed Bioequivalence Studies* is available to assist sponsors.
- The test and reference products should be administered with about 8 ounces (240 milliliters) of water to an appropriate number of subjects.
- Generally, the highest marketed strength should be administered as a single unit. If warranted, to achieve sufficient bioanalytical sensitivity multiple units of the highest strength can be administered, provided the total single dose remains within the labeled dose range and the total dose is safe for administration to the study subjects.
- An adequate washout period (e.g.,  $\geq 5$  half-lives of the moieties to be measured) should separate each treatment.
- The lot numbers of both test and reference listed products and the expiration date for the reference product should be stated. We recommend that the assayed drug content of the test product batch not differ from the reference product by more than +/- 5 percent. The sponsor should include a statement of the composition of the test product and, if possible, a side-by-side comparison of the compositions of test and reference listed products. In accordance with 21 CFR 320.38, and 21 CFR 320.63, samples of the test and reference listed product must be retained for at least 5 years. For additional information, please refer to the FDA guidance for industry on *Handling and Retention of Bioavailability and Bioequivalence Testing Samples*.
- Before and during each study phase, we recommend that subjects (1) be allowed water as desired except for 1 hour before and after drug administration, (2) be provided standard meals no less than 4 hours after drug administration, and (3) abstain from alcohol for 24 hours before each study period and until after the last sample from each period is collected.

**Sample collection and sampling times**

- We recommend that under normal circumstances, blood, rather than urine or tissue, be used. In most cases, drug or metabolites are measured in serum or plasma. However, in certain cases, such as when an assay of sufficient sensitivity cannot be developed for plasma, whole blood may be more appropriate for analysis. We recommend that blood samples be drawn at

*Contains Nonbinding Recommendations*

967 appropriate times to describe the absorption, distribution, and elimination phases of the drug.  
968 For most drugs we recommend that 12 to 18 samples, including a pre-dose sample, be  
969 collected per subject per dose. ***This sampling should continue for at least three or more***  
970 ***terminal elimination half-lives of the drug*** to capture 90 percent of the relevant AUC. For  
971 multiple-dose studies, sampling should occur across the dose interval and include the  
972 beginning and the end of the interval. The exact timing for sample collection depends on the  
973 nature of the drug and the rate of input from the administered dosage form. The sample  
974 collection should be spaced in such a way that the maximum concentration ( $C_{\max}$ ) of the drug  
975 in the blood and terminal elimination rate constant ( $\lambda_z$ ) can be estimated accurately.

976  
977 Three or more samples should be obtained during the terminal log-linear phase to obtain an  
978 accurate estimate of  $\lambda_z$  from linear regression. We recommend recording the actual clock  
979 time when samples are drawn, as well as the elapsed time related to drug administration.  
980

981 **Subjects with pre-dose plasma concentrations**  
982

- 983 • If the pre-dose concentration is  $\leq 5$  percent of  $C_{\max}$  value in that subject, the subject's data  
984 without any adjustments can be included in all PK measurements and calculations. We  
985 recommend that if the pre-dose value is  $> 5$  percent of  $C_{\max}$ , the subject should be dropped  
986 from all PK evaluations. The subject data should be reported and the subject should be  
987 included in safety evaluations.  
988

989 **Data deletion because of vomiting**  
990

- 991 • We recommend that data from subjects who experience emesis during the course of a study  
992 for immediate-release products be deleted from statistical analysis if vomiting occurs at or  
993 before 2 times median  $T_{\max}$ . For modified-release products, subjects who experience emesis  
994 at any time during the labeled dosing interval should not be included in PK analysis.  
995

996 **Data submission and analysis**  
997

998 The following PK information is recommended for submission:  
999

- 1000 • Plasma concentrations and time points.
- 1001 • Subject, period, sequence, treatment.
- 1002 • Intersubject, intrasubject, and/or total variability, if available.
- 1003 • For single-dose studies:  $AUC_{0-t}$ ,  $AUC_{0-inf}$ ,  $C_{\max}$ ,  $T_{\max}$ ,  $\lambda_z$ , and  $t_{1/2}$ .
- 1004 • For steady-state studies:  $AUC_{0-tau}$ ,  $C_{\max ss}$ ,  $T_{\max}$ ,  $C_{\min ss}$  (lowest concentration in a dosing  
1005 interval),  $C_{\text{trough}}$  (concentration at the end of the dosing interval),  $C_{\text{avss}}$  (average  
1006 concentration during a dosing interval), degree of fluctuation  $[(C_{\max} - C_{\min})/C_{\text{avss}}]$ , swing  
1007  $[(C_{\max ss} - C_{\min ss})/C_{\min ss}]$ .  $C_{\text{trough}}$  should be measured for several dosing intervals to assess  
1008 whether steady-state was achieved.

*Draft — Not for Implementation*

*Contains Nonbinding Recommendations*

- 1009       • In addition to the above information, clearance and volume of distribution should be  
1010       reported for BA studies.

1011  
1012 In addition, we recommend that the following statistical information be provided for  $AUC_{0-t}$ ,  
1013  $AUC_{0-\infty}$ , and  $C_{max}$ :

- 1014  
1015       • Geometric means  
1016       • Arithmetic means  
1017       • Geometric mean ratios  
1018       • 90 percent Confidence intervals (CI)

1019  
1020 We also recommend that logarithmic transformation be provided for measures used for BE  
1021 demonstration. An FDA guidance for industry, *Statistical Approaches to Establishing*  
1022 *Bioequivalence*, is available.

1023  
1024 **Rounding off of confidence interval values**

1025  
1026 We recommend that applicants *not round off* CI values; therefore, to pass a CI limit of 80 to 125  
1027 percent, the value should be at least 80.00 percent and not more than 125.00 percent.

1028  
1029